← Leaderboards
Jayakrishna Ambati
University Of Kentucky
$25,438,584
Attributed
$30,293,795
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,293,795 · 14
By mechanism
R01$24,914,526 · 11
DP1$3,972,750 · 1
RC1$1,000,000 · 1
R21$406,519 · 1
Top collaborators
- Bradley David Gelfand21 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Douglas Allen Andres$9,903,896
- Judit Zsuzsanna Baffi$111,330
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularBlindnessInsightCellsAffectPathway InteractionsAge Related Macular DegenerationSignal TransductionBlood VesselsRetinaMouse ModelMediatingProgramsImmuneChoroidal NeovascularizationPathologyAnimal ModelComplexAlzheimer&AposPreventStructure Of Retinal Pigment EpitheliumBiochemicalGeneticCytokine
Grant awards (67)
Cytosolic SINE retrotransposable element cDNA and mitochondrial DNA in aging retina$614,163
R01 · FY2025 · AG · contact PI
Defining the role of SINE retrotransposons and inflammasome activation in Alzheimer's disease$608,367
R01 · FY2025 · AG · contact PI
Cytosolic SINE retrotransposable element cDNA and mitochondrial DNA in aging retina$631,751
R01 · FY2024 · AG · contact PI
Defining the role of SINE retrotransposons and inflammasome activation in Alzheimer's disease$620,783
R01 · FY2024 · AG · contact PI
Nlrp3 inflammasome activation in early diabetic retinopathy$472,784
R01 · FY2024 · EY · contact PI
Cytosolic SINE retrotransposable element cDNA and mitochondrial DNA in aging retina$626,696
R01 · FY2023 · AG · contact PI
Defining the role of SINE retrotransposons and inflammasome activation in Alzheimer's disease$620,783
R01 · FY2023 · AG · contact PI
Nlrp3 inflammasome activation in early diabetic retinopathy$472,784
R01 · FY2023 · EY · contact PI
Visual system and cognitive biology in normal animals versus in an animal model of Alzheimer's disease with or without diabetes treated with solo or dual inflammasome inhibitors$403,750
R01 · FY2023 · EY · contact PI
Defining the role of SINE retrotransposons and inflammasome activation in Alzheimer's disease$620,783
R01 · FY2022 · AG · contact PI
Non-canonical inflammasome in activation in RPE degeneration$564,039
R01 · FY2022 · EY · contact PI
Nlrp3 inflammasome activation in early diabetic retinopathy$458,602
R01 · FY2022 · EY · contact PI
Antigen-independent suppression of ocular angiogenesis via the Fc receptor$391,639
R01 · FY2022 · EY · contact PI
Nlrp3 inflammasome activation in early diabetic retinopathy - Administrative Supplement ERG Request$52,750
R01 · FY2022 · EY · contact PI
Non-canonical inflammasome in activation in RPE degeneration$564,039
R01 · FY2021 · EY · contact PI
Nlrp3 inflammasome activation in early diabetic retinopathy$462,151
R01 · FY2021 · EY · contact PI
Inflammasome-based Alzheimer's disease therapy in the context of diabetes$403,748
R01 · FY2021 · EY · contact PI
Antigen-independent suppression of ocular angiogenesis via the Fc receptor$391,639
R01 · FY2021 · EY · contact PI
Non-canonical inflammasome in activation in RPE degeneration$581,482
R01 · FY2020 · EY · contact PI
Nlrp3 inflammasome activation in early diabetic retinopathy$484,500
R01 · FY2020 · EY · contact PI
Antigen-independent suppression of ocular angiogenesis via the Fc receptor$403,750
R01 · FY2020 · EY · contact PI
Non-canonical inflammasome in activation in RPE degeneration$581,482
R01 · FY2019 · EY · contact PI
Non-canonical inflammasome in activation in RPE degeneration$403,750
R01 · FY2019 · EY · contact PI
Antigen-independent suppression of ocular angiogenesis via the Fc receptor$403,750
R01 · FY2019 · EY · contact PI
Antigen-independent suppression of ocular angiogenesis via the Fc receptor$161,500
R01 · FY2019 · EY · contact PI
Form and function of our Janus faced genome$790,000
DP1 · FY2018 · GM · contact PI
Antigen-independent suppression of ocular angiogenesis via the Fc receptor$403,750
R01 · FY2018 · EY · contact PI
Form and function of our Janus faced genome$790,000
DP1 · FY2017 · GM · contact PI
Inflammasome Activation in Geographic Atrophy$658,686
R01 · FY2017 · EY · contact PI
Form and function of our Janus faced genome$790,000
DP1 · FY2016 · GM · contact PI
Inflammasome Activation in Geographic Atrophy$669,209
R01 · FY2016 · EY · contact PI
Functional studies of DICER1 and Alu RNA in geographic atrophy$512,674
R01 · FY2016 · EY · contact PI
Form and function of our Janus faced genome$835,784
DP1 · FY2015 · GM · contact PI
Inflammasome Activation in Geographic Atrophy$655,219
R01 · FY2015 · EY · contact PI
Functional studies of DICER1 and Alu RNA in geographic atrophy$625,541
R01 · FY2015 · EY · contact PI
Form and Function Function of our Janus faced genome$16,716
DP1 · FY2015 · GM · contact PI
Form and function of our Janus faced genome$750,250
DP1 · FY2014 · GM · contact PI
Inflammasome Activation in Geographic Atrophy$657,112
R01 · FY2014 · EY · contact PI
Functional studies of DICER1 and Alu RNA in geographic atrophy$613,171
R01 · FY2014 · EY · contact PI
Functional studies of DICER1 and Alu RNA in geographic atrophy$524,861
R01 · FY2013 · EY · contact PI
Endogenous Specific Inhibitor of Corneal Lymphangiogenesis$338,580
R01 · FY2013 · EY · contact PI
Functional studies of DICER1 and Alu RNA in geographic atrophy$114,148
R01 · FY2013 · EY · contact PI
Functional studies of DICER1 and Alu RNA in geographic atrophy$552,485
R01 · FY2012 · EY · contact PI
Endogenous Specific Inhibitor of Corneal Lymphangiogenesis$356,400
R01 · FY2012 · EY · contact PI
Functional studies of DICER1 and Alu RNA in geographic atrophy$351,096
R01 · FY2012 · EY · contact PI
Endogenous Specific Inhibitor of Corneal Lymphangiogenesis$356,400
R01 · FY2011 · EY · contact PI
Pro-and anti-angiogenic effects of vascular endothelial growth factor-A$351,600
R01 · FY2011 · EY · contact PI
Intrinsic anti-angiogenic activity of siRNA$351,600
R01 · FY2011 · EY · contact PI
Endogenous Specific Inhibitor of Corneal Lymphangiogenesis$82,170
R01 · FY2011 · EY · contact PI
CCR3: a molecular marker for neovascular AMD$500,000
RC1 · FY2010 · EY · contact PI
Endogenous Specific Inhibitor of Corneal Lymphangiogenesis$371,250
R01 · FY2010 · EY · contact PI
Pro-and anti-angiogenic effects of vascular endothelial growth factor-A$362,588
R01 · FY2010 · EY · contact PI
Intrinsic anti-angiogenic activity of siRNA$362,588
R01 · FY2010 · EY · contact PI
Novel TLR3 inhibitors for geographic atrophy of age-related macular degeneration$183,769
R21 · FY2010 · EY · contact PI
Pro-and anti-angiogenic effects of vascular endothelial growth factor-A$89,800
R01 · FY2010 · EY · contact PI
CCR3: a molecular marker for neovascular AMD$500,000
RC1 · FY2009 · EY · contact PI
Intrinsic anti-angiogenic activity of siRNA$431,640
R01 · FY2009 · EY · contact PI
Intrinsic anti-angiogenic activity of siRNA$366,250
R01 · FY2009 · EY · contact PI
Pro-and anti-angiogenic effects of vascular endothelial growth factor-A$361,879
R01 · FY2009 · EY · contact PI
Novel TLR3 inhibitors for geographic atrophy of age-related macular degeneration$222,750
R21 · FY2009 · EY · contact PI
Intrinsic anti-angiogenic activity of siRNA$366,250
R01 · FY2008 · EY · contact PI
Pro-and anti-angiogenic effects of vascular endothelial growth factor-A$355,097
R01 · FY2008 · EY · contact PI
Pro-and anti-angiogenic effects of vascular endothelial growth factor-A$362,763
R01 · FY2007 · EY · contact PI
Novel Mouse Models of Age-Related Macular Degeneration$321,824
R01 · FY2007 · EY · contact PI
Novel Mouse Models of Age-Related Macular Degeneration$323,636
R01 · FY2006 · EY · contact PI
Novel Mouse Models of Age-Related Macular Degeneration$331,425
R01 · FY2005 · EY
Novel Mouse Models of Age-Related Macular Degeneration$331,369
R01 · FY2004 · EY